Core Viewpoint - BeiGene reported a total revenue of 38.205 billion yuan for the fiscal year 2025, representing a year-on-year growth of 40.4% driven by product revenue growth and improved operational efficiency through cost management [1] Group 1: Financial Performance - The net profit attributable to the parent company reached 1.422 billion yuan during the reporting period [1] - Product revenue amounted to 37.77 billion yuan, showing a year-on-year increase of 39.9% [1] Group 2: Product Sales - The global sales of the product Brukinsa® (Zebutinib) reached 28.067 billion yuan, with a year-on-year growth of 48.8% [1] - In the U.S. market, Brukinsa® sales were 20.206 billion yuan, reflecting a year-on-year increase of 45.5% [1] - In Europe, Brukinsa® sales reached 4.265 billion yuan, growing by 66.4% year-on-year [1] - In China, Brukinsa® sales were 2.472 billion yuan, with a year-on-year growth of 33.1% [1] - Another core product, Tislelizumab (百泽安®), achieved global sales of 5.297 billion yuan, marking an 18.6% increase year-on-year [1] Group 3: Future Prospects - BeiGene plans to submit a new indication application for Tislelizumab combined with Zanidatamab (Zanidatamab) for first-line treatment of HER2-positive gastric adenocarcinoma in adults in the U.S. and China in the first half of 2026 [1] - The company anticipates a regulatory decision in Japan for the same indication in the second half of 2026 [1]

Core Viewpoint - BeiGene has reported a significant increase in revenue and net profit for the fiscal year 2025, indicating a successful transition from a loss-making entity to a profitable one, driven by strong product sales and effective cost management [1][3]. Financial Performance - Total revenue for 2025 reached RMB 38.205 billion, a year-on-year increase of 40.4% [1]. - Net profit attributable to the parent company was RMB 1.422 billion [1]. - Product revenue amounted to RMB 37.770 billion, reflecting a growth of 39.9% [1]. Product Performance - The sales of the leading product, Brukinsa® (Zebutinib), reached RMB 28.067 billion, marking a 48.8% increase [1]. - In the U.S., Brukinsa® sales were RMB 20.206 billion, up 45.5% [1]. - In Europe, sales were RMB 4.265 billion, a growth of 66.4% [1]. - In China, sales reached RMB 2.472 billion, increasing by 33.1% [1]. Market Expansion and Clinical Trials - Brukinsa® is now approved in over 75 markets globally, establishing itself as the most widely approved BTK inhibitor [2]. - Upcoming clinical trials include a mid-term analysis of the MANGROVE trial for Brukinsa® in combination with Rituximab for adult patients with mantle cell lymphoma [2]. - The sales of another key product, Tislelizumab (百泽安®), reached RMB 5.297 billion, an 18.6% increase [2]. Future Projections - Revenue for 2026 is projected to be between RMB 43.6 billion and RMB 45 billion, with a gross margin expected to remain high at around 80% [4]. - Research and development expenses are anticipated to be between RMB 33.3 billion and RMB 34.8 billion [4]. Pipeline and Innovation - The company is advancing several late-stage products in the hematologic oncology field, including the BCL2 inhibitor, which has received approval for its first global marketing application in China [4]. - The introduction of BTK inhibitors and IRAK4 degraders into autoimmune diseases represents a strategic expansion into non-oncology markets [5]. Market Position and Valuation - Despite achieving profitability, the company's market valuation remains high, with a significant price-to-earnings ratio, indicating that the market views it as a growth stock rather than a value stock [5].

Core Insights - The company reported a significant increase in product revenue and total revenue for the fiscal year 2025, with product revenue reaching 37.77 billion yuan, a year-on-year increase of 39.9%, and total revenue at 38.205 billion yuan, up 40.4% [1] - The net profit attributable to the parent company was 1.422 billion yuan, while total assets increased by 34.1% to 57.423 billion yuan, and equity attributable to the parent company rose by 26.6% to 30.601 billion yuan [1] Product Performance - The global sales of Baiyueze® reached 28.067 billion yuan, marking a 48.8% year-on-year growth, solidifying its position as a global leader in the BTK inhibitor market [2] - Sales in the U.S. amounted to 20.206 billion yuan, a 45.5% increase, while European sales were 4.265 billion yuan, up 66.4%, and sales in China totaled 2.472 billion yuan, increasing by 33.1% [2] - Bai Ze An® achieved global sales of 5.297 billion yuan, reflecting an 18.6% year-on-year growth, and sales from Amgen's licensed products reached 3.471 billion yuan, up 33.6% [2] Clinical Development and Regulatory Approvals - Baiyueze® is the most widely approved BTK inhibitor globally, with over 45 clinical trials conducted across more than 30 countries, enrolling over 7,900 patients [3] - The drug has received regulatory approvals in over 75 markets and demonstrated significant benefits in progression-free survival (PFS) in clinical trials, reinforcing its status as a preferred BTK inhibitor [3] - Bai Ze An® has shown potential across various tumor types, with clinical trials involving over 15,800 participants in more than 33 countries, and has been approved in over 50 markets [4] - The company plans to submit new indications for Bai Ze An® in the U.S. and China in the first half of 2026, with expectations for regulatory decisions in Japan by the second half of 2026 [4]

Market Overview - On November 19, Hong Kong stocks experienced narrowed volatility, opening high but trending downwards, fluctuating between 25,742 and 26,045 points. The Hang Seng Index closed at 25,830 points, down 99 points (0.4%) [1] - The Hang Seng Tech Index fell by 38 points (0.7%), closing at 5,606 points, with total market turnover slightly decreasing to HKD 211.4 billion [1] - Net inflow from the Hong Kong Stock Connect further decreased to HKD 6.59 billion [1] Company Performance - Xiaomi Group (1810 HK) reported a 22.3% year-on-year increase in revenue for Q3, but a 2.4% quarter-on-quarter decline, meeting expectations. However, concerns over rising memory costs and slowing smartphone demand pressured the company's gross margin, leading to a 4.8% drop in stock price [4] - The electric vehicle segment recorded quarterly profitability, but the outlook for the new energy vehicle industry has become increasingly pessimistic, compounded by the expiration of tax exemption policies next year [4] Industry Dynamics Automotive Sector - The overall new energy vehicle sector has been trending downwards, with companies like NIO and Li Auto experiencing declines of 0.3% to 2.6% [4] Pharmaceutical Sector - The Hang Seng Healthcare Index fell by 1.7%, but major companies saw limited declines. The National Medical Products Administration is expected to approve 43 innovative drugs by mid-2025, reflecting improved R&D capabilities among Chinese firms and government support for innovation [4] - BeiGene (6160 HK) announced positive clinical research results for its HER2-targeted bispecific antibody, leading to a 1.0% increase in its stock price [4] Renewable Energy and Utilities - The renewable energy sector showed mixed performance, with the photovoltaic segment continuing to decline. Companies like Xinyi Solar (968 HK) and Flat Glass Group (6865 HK) fell by 1.4% to 1.6% [5] - Some environmental stocks received support due to their high dividends and stable business models, with companies like China Everbright Environment (257 HK) and GCL-Poly Energy (1330 HK) rising by 1.2% to 2.0% [5]

Market Overview - On November 17, U.S. interest rate cut expectations cooled, leading to a decline in technology stocks, with major Asia-Pacific markets generally falling. The Hang Seng Index closed at 25,930 points, down 454 points (1.7%), breaching the psychological level of 26,000 points [1] - The Hang Seng Technology Index fell by 111 points (1.9%), closing at 5,645 points, with total market turnover increasing to 242.1 billion HKD [1] Company Specifics - Xpeng Motors (9868 HK) reported a total revenue of 20.38 billion HKD for Q3, a year-on-year increase of 102%. However, the company’s Q4 revenue guidance of 21.5 billion to 23 billion HKD, representing a year-on-year growth of 33.5%-42.8%, was below market expectations, leading to a 10.5% drop in its stock price [4] - Alibaba (9988 HK) saw a brief increase in stock price due to the launch of its Qianwen APP but ultimately closed down 0.2% [1] - Tencent (700 HK) and Kuaishou (1024 HK) also experienced declines of 2.0% and 3.2%, respectively [1] Industry Dynamics - The automotive sector saw a broad decline, particularly affecting Xpeng Motors due to concerns over future delivery growth amid the phasing out of new energy vehicle subsidies [4] - The healthcare sector, represented by the Hang Seng Healthcare Index, fell by 1.7%, but major companies did not experience significant declines. Notably, BeiGene (6160 HK) saw a 1.0% increase in stock price following positive clinical research results for its HER2-targeted therapies [5] - The renewable energy and utility sectors also faced declines, with stocks like Xinyi Solar (968 HK) and GCL-Poly Energy (3800 HK) dropping between 2.9% and 8.6% [5]

Core Viewpoint - BeiGene reported strong financial performance for the first half of 2025, achieving significant revenue growth and profitability, driven by product sales and effective cost management [1][2][3] Financial Performance - Total revenue for the first half of 2025 reached RMB 17.518 billion, a year-on-year increase of 46.0% [1] - Product revenue amounted to RMB 17.360 billion, reflecting a growth of 45.8% compared to the previous year [1] - Operating profit was RMB 799 million, and net profit attributable to shareholders was RMB 450 million, marking a turnaround from losses in the same period last year [1] - The company updated its revenue guidance for 2025, now expecting total revenue between RMB 35.8 billion and RMB 38.1 billion, with a gross margin forecast of 80% to 90% [1] Product Performance - The BTK inhibitor, Zanubrutinib (Brukinsa), achieved global sales of RMB 12.527 billion in the first half of 2025, a 56.2% increase year-on-year [3] - In the U.S. market, Zanubrutinib sales reached RMB 8.958 billion, up 51.7%, driven by strong demand across all indications [3] - The PD-1 inhibitor, Tislelizumab, generated sales of RMB 2.643 billion, a 20.6% increase, benefiting from new indications and increased hospital access in China [4] R&D Pipeline - The company is at a critical juncture in its R&D pipeline, expecting over 20 milestone events in the next 18 months across hematological and solid tumor indications [6] - BeiGene has advanced 15 new molecular entities into clinical trials from 2019 to 2023, with over 10 new entities entering trials in 2024 alone [6] - The company has established a robust global clinical development platform, conducting over 170 trials across 40 countries with more than 25,000 patients enrolled [6] Future Developments - In hematological oncology, BeiGene has three fully owned products, including Zanubrutinib and two candidates in Phase 3 trials, which are expected to meet unmet needs in chronic lymphocytic leukemia (CLL) [7] - In solid tumors, the company is advancing multiple products, including a CDK4 inhibitor for breast cancer and a PRMT5 inhibitor, with clinical trials expected to commence in the near future [8][9]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 BeOne Medicines Ltd. 百濟神州有限公司 （根據瑞士法律註冊成立的公司） （股份代號：06160） 海外監管公告 本公告乃百濟神州有限公司（BeOne Medicines Ltd., 「本公司」）根據香港聯合交易 所有限公司證券上市規則第13.10B條作出。 A 股代码：688235 A 股简称：百济神州 公告编号：2025-028 港股代码：06160 港股简称：百济神州 美股代码：ONC 百济神州有限公司 2025年半年度主要财务数据公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 特别提示： 本公告所载的百济神州有限公司（以下简称"百济神州"或"公司"）2025 年半年度主要财务数据为初步核算数据，未经会计师事务所审计，具体数据以公司 2025 年半年度报告中披露的数据为准，提请投资者注意投 ...